ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

Management expansion strengthens capabilities in developing new class of alpha radioligand therapies CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ — ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class…